שווי מתואם לחוב ומזומנים Innate Pharma S.A (IPHA)

The market capitalization trend for Innate Pharma S.A. (IPHA) on the GURU.Markets platform is 173.72, supported by a stable moat derived from its innate immunity activation platform and licensing fees. The French developer dictates payment terms thanks to exclusive patents and alliances with market leaders. High barriers to entry are created by antibody patents and stringent oversight from the EMA and FDA.

Enterprise value represents the total acquisition cost of an asset, combining market capitalization and net debt, which allows for an assessment of the actual costs of buying out a business. By analyzing the aggregate valuation of Innate Pharma S.A. (IPHA), an investor can see how high R&D expenditures on laboratories are balanced by strategic partnerships, determining a fair value threshold relative to capital drawdown risks.